Host-Directed and Immune-Based Therapies for Human Immunodeficiency Virus Infection
- From the AIDS Clinical Trials Unit, Case Western Reserve University and University Hospitals of Cleveland, Cleveland, Ohio. Requests for Reprints: Michael M. Lederman, MD, Department of Medicine/Division of Infectious Diseases, University Hospitals of Cleveland, 11100 Euclid Avenue, Cleveland, OH 44106. Acknowledgments: The author thanks Drs. Jerrold Ellner, Jonathan Kagan, Norman Letvin, and Robert Schooley for their thoughtful comments. Grant Support: By the National Institutes of Health (AI 25879).
Abstract
This essay reviews the rationale underlying host-directed or immune-based therapeutic strategies for human immunodeficiency virus (HIV) infection and its complications. These approaches have seen only limited trial in the past 10 years, but as more is learned about the immunopathogenesis of HIV disease and as the limitations of virus-directed therapies become more apparent, the need to pursue other therapeutic avenues has become increasingly important. Moreover, properly designed trials of host-directed and immune-based therapies can provide key insights into the pathogenesis of HIV disease that may be otherwise unattainable through in vitro studies.
- Copyright ©2004 by the American College of Physicians
Most Read
